Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Study of Oral Cabozantinib in Metastatic Medullary Thyroid Cancer
2013-003402-40Phase 4Active
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cabozantinib in Medullary Thyroid Cancer (MTC), sponsored by Exelixis, Inc. Primary endpoint: Progression-free survival. Started Dec 2014; status: active.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2013-003402-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003402-40.